Kemal Panç
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kemal Panç has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Sümeyye Sekmen
Department of Radiology, Recep Tayyip Erdogan University, Rize, Turkey
3 shared publications - Enes Gurun
Department of Radiology Samsun University Faculty of Medicine Samsun Turkey
2 shared publications - Mustafa Basaran
Department of Radiology Samsun University Faculty of Medicine Samsun Turkey
2 shared publications - Fatma Beyazal Çeliker
Department of Radiology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, Turkey
1 shared publication - Filiz Taşçi
Department of Radiology, Recep Tayyip Erdogan University, Rize, Turkey
1 shared publication - Hande Melike Bülbül
Department of Radiology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize 53020, Türkiye
1 shared publication
Latest Publications
- 22 November 2025
- Published by Elsevier in Clinical Imaging
- Vol. 129, 110680
Investigation of the relationship between background parenchymal enhancement and breast cancer using 3.0 Tesla magnetic resonance imaging
- 22 November 2025
- Published by Elsevier in Clinical Imaging
- Vol. 129, 110680
Investigation of the relationship between background parenchymal enhancement and breast cancer using 3.0 Tesla magnetic resonance imaging
- 7 November 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (4) , 808-816
Integrative Machine Learning Model Leveraging DCE ‐ MRI and PSA Values for Advanced Risk Stratification in Prostate Cancer
Purpose: Accurate grading of prostate cancer is critical for treatment strategies and risk stratification. This study aims to develop a machine learning (ML) model integrating Dynamic Contrast‐Enhanced Magnetic Resonance Imaging (DCE‐MRI) pharmacokinetic parameters with Prostate‐Specific Antigen (PSA) values to predict ISUP grade metastatic risk groups. Methods: This retrospective study included 102 patients with histologically confirmed prostate cancer. DCE‐MRI pharmacokinetic parameters (Ktrans, Kep, Ve, CER, MaxSlope, IAUGC) were standardized. The dataset was balanced using the Synthetic Minority Oversampling Technique and split into training, validation, and test sets. ML models, including Random Forest, were evaluated using Area Under the Curve (AUC) values. Results: The Random Forest classifier achieved the highest performance, with an AUC of 0.92. Precision‐recall analysis identified an optimal threshold of 0.3, balancing sensitivity and specificity for high‐risk group detection. SHAP analysis highlighted PSA, MaxSlope, and Kep as key predictors contributing to model accuracy. Conclusion: Integrating DCE‐MRI parameters with PSA values using ML algorithms enhances the prediction of ISUP grade metastatic risk groups. This method provides a robust tool for metastasis screening and personalized treatment in prostate cancer.
- 7 November 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (4) , 808-816
Integrative Machine Learning Model Leveraging DCE ‐ MRI and PSA Values for Advanced Risk Stratification in Prostate Cancer
Purpose: Accurate grading of prostate cancer is critical for treatment strategies and risk stratification. This study aims to develop a machine learning (ML) model integrating Dynamic Contrast‐Enhanced Magnetic Resonance Imaging (DCE‐MRI) pharmacokinetic parameters with Prostate‐Specific Antigen (PSA) values to predict ISUP grade metastatic risk groups. Methods: This retrospective study included 102 patients with histologically confirmed prostate cancer. DCE‐MRI pharmacokinetic parameters (Ktrans, Kep, Ve, CER, MaxSlope, IAUGC) were standardized. The dataset was balanced using the Synthetic Minority Oversampling Technique and split into training, validation, and test sets. ML models, including Random Forest, were evaluated using Area Under the Curve (AUC) values. Results: The Random Forest classifier achieved the highest performance, with an AUC of 0.92. Precision‐recall analysis identified an optimal threshold of 0.3, balancing sensitivity and specificity for high‐risk group detection. SHAP analysis highlighted PSA, MaxSlope, and Kep as key predictors contributing to model accuracy. Conclusion: Integrating DCE‐MRI parameters with PSA values using ML algorithms enhances the prediction of ISUP grade metastatic risk groups. This method provides a robust tool for metastasis screening and personalized treatment in prostate cancer.
- 16 April 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (6) , 1296-1303
Diagnostic Value of Dual‐Energy CT Iodine Mapping in Differentiating Malignant and Benign Cervical Lymphadenopathies
Purpose: To evaluate the diagnostic accuracy of Dual‐Energy Computed Tomography (DECT) in distinguishing malignant from benign cervical lymph nodes in neck carcinoma based on iodine concentration and normalized spectral attenuation (Hounsfield Unit, HU) values.Methods: Retrospective DECT scan analysis was performed on 52 neck carcinoma patients, analyzing 52 metastatic and 28 reactive lymph nodes. Iodine concentration (mg/mL) and spectral HU values were measured with circular regions of interest on iodine maps. Metastatic nodes included 27 from squamous cell carcinoma (SCC), 19 from lymphoma, and 6 from papillary thyroid carcinoma (PTC).Results: Metastatic lymph nodes had lower iodine levels than reactive nodes (1.45 vs. 1.85 mg/mL, p = 0.011). No significant difference in spectral HU values was found (117 vs. 111 HU, p = 0.328). An iodine threshold of 1.62 mg/mL demonstrated 71% sensitivity and 77% specificity for detecting malignancy (AUC = 0.673, 95% CI: 0.54–0.80, p = 0.011). SCC metastases had lower iodine levels than reactive nodes (1.33 vs. 1.85 mg/mL, p < 0.001), while PTC metastases had higher levels (2.39 vs. 1.85 mg/mL, p = 0.038).Conclusion: DECT iodine quantification improves the detection of cervical lymph node metastases, particularly in cases with equivocal size criteria. Incorporating iodine measurements with tumor type knowledge improves diagnostic accuracy, aiding in prognosis and treatment planning.
- 16 April 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (6) , 1296-1303
Diagnostic Value of Dual‐Energy CT Iodine Mapping in Differentiating Malignant and Benign Cervical Lymphadenopathies
Purpose: To evaluate the diagnostic accuracy of Dual‐Energy Computed Tomography (DECT) in distinguishing malignant from benign cervical lymph nodes in neck carcinoma based on iodine concentration and normalized spectral attenuation (Hounsfield Unit, HU) values.Methods: Retrospective DECT scan analysis was performed on 52 neck carcinoma patients, analyzing 52 metastatic and 28 reactive lymph nodes. Iodine concentration (mg/mL) and spectral HU values were measured with circular regions of interest on iodine maps. Metastatic nodes included 27 from squamous cell carcinoma (SCC), 19 from lymphoma, and 6 from papillary thyroid carcinoma (PTC).Results: Metastatic lymph nodes had lower iodine levels than reactive nodes (1.45 vs. 1.85 mg/mL, p = 0.011). No significant difference in spectral HU values was found (117 vs. 111 HU, p = 0.328). An iodine threshold of 1.62 mg/mL demonstrated 71% sensitivity and 77% specificity for detecting malignancy (AUC = 0.673, 95% CI: 0.54–0.80, p = 0.011). SCC metastases had lower iodine levels than reactive nodes (1.33 vs. 1.85 mg/mL, p < 0.001), while PTC metastases had higher levels (2.39 vs. 1.85 mg/mL, p = 0.038).Conclusion: DECT iodine quantification improves the detection of cervical lymph node metastases, particularly in cases with equivocal size criteria. Incorporating iodine measurements with tumor type knowledge improves diagnostic accuracy, aiding in prognosis and treatment planning.
- Open Access
- 23 August 2024
- Published by PAGEPress Publications in Chest Disease Reports
- Vol. 12
A confusing lesion: pulmonary Inflammatory Myofibroblast Tumour
Inflammatory Myofibroblastic Tumours (IMT), also known as plasma cell granuloma, is a mesenchymal neoplasm that can be observed in almost every tissue. IMT is very rare with an incidence of approximately 0.04-1% of all pulmonary masses in adults. In children, it is the most common primary mass of the lung. Imaging findings of IMT are variable and nonspecific, probably due to fibrosis and cellular infiltration. They can cause difficulties in the diagnostic process due to differences in imaging characteristics.
- 23 August 2024
- Published by PAGEPress Publications in Chest Disease Reports
- Vol. 12
Open AccessA confusing lesion: pulmonary Inflammatory Myofibroblast Tumour
Inflammatory Myofibroblastic Tumours (IMT), also known as plasma cell granuloma, is a mesenchymal neoplasm that can be observed in almost every tissue. IMT is very rare with an incidence of approximately 0.04-1% of all pulmonary masses in adults. In children, it is the most common primary mass of the lung. Imaging findings of IMT are variable and nonspecific, probably due to fibrosis and cellular infiltration. They can cause difficulties in the diagnostic process due to differences in imaging characteristics.